Palliation of Pelvic and Head and Neck Cancer with Paclitaxel and a Novel Radiotherapy Regimen

Carrascosa, Luis A.; Yashar, Catheryn M.; Paris, Kristie J.; LaRocca, Renato; Faught, S.R.; Spanos, William J.

doi:10.1089/jpm.2006.0192

Cited by 29 publications

(27 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…No Grade 3 or higher toxicity was reported[9]. In addition, there have been efforts to combine systemic therapy with this palliative regimen[17]. Carrascosa and colleagues reported on 20 patients with advanced pelvic (n = 13) or head and neck malignancies (n = 7) who underwent the RTOG 8502 regimen concurrently with low dose paclitaxel 60 mg/m 2 with each cycle of RT.…”

Section: Discussionmentioning

confidence: 99%

Palliative head and neck radiotherapy with the RTOG 8502 regimen for incurable primary or metastatic cancers

et al. 2015

View full text Add to dashboard Cite

Objectives To report on our institutional experience of palliative radiotherapy (RT) of cancers in the head and neck by the RTOG 8502 ‘QUAD SHOT’ regimen. Methods Seventy-five patients completed at least 1 cycle of palliative RT to the head and neck for primary or metastatic disease based on the RTOG 8502 regimen (3.7 Gy twice daily over 2 consecutive days at 4 week intervals per cycle) between 2/2005 and 7/2014. Results Median patient age was 76 years (range 23 to 97). The most common histologies were squamous cell carcinoma (55%), non-anaplastic thyroid carcinoma (10%) and salivary gland carcinoma (9%). Thirty patients (40%) received prior RT at the palliative site. Twenty-eight patients (37%) completed at least three RTOG 8502 cycles. Sixty-five percent of all patients had a palliative response. Median overall survival was 5.67 months (range, 0.20 - 34.5). Grade 3 toxicity in 4 patients (5%) consisted of acute dermatitis and functional mucositis. Palliative response was significantly correlated with increasing number of RTOG 8502 cycles (p=0.012), but not KPS, prior RT, palliative chemotherapy, prior surgery, histology or stage. On survival analysis, palliative response (p<0.001), KPS ≥70 (p=0.001), and greater number of RTOG 8502 cycles (p=0.022) remained independent predictors of improved survival. Conclusions For patients with incurable malignant disease in the head and neck, the palliative RTOG 8502 ‘QUAD SHOT’ regimen provides excellent rates of palliative response with minimal associated toxicity. Patients who are able to complete greater number of RT cycles have higher rates of palliative response and overall survival.

show abstract

Section: Discussionmentioning

confidence: 99%

Palliative head and neck radiotherapy with the RTOG 8502 regimen for incurable primary or metastatic cancers

et al. 2015

View full text Add to dashboard Cite

show abstract

“…In a phase I/II trial, Paris et al reported that 33 of 39 patients (85%) received palliation from this regimen with acceptable side effects. No late complications were reported; however, as acknowledged by the investigators, “the limited life expectancy of these patients could potentially mask the problems.” In a recently published update of the Louisville experience, Carrascosa et al13 confirmed that nearly 90% of patients derived symptomatic relief using this short‐course regimen. Finally, Corry et al14 from the Peter MacCullum Cancer Center reported on 30 patients treated with the RTOG 85‐02 regimen, which was referred to as “the quad‐shot.” The reported rate of objective tumor response was 53%.…”

Section: Discussionmentioning

confidence: 99%

Palliative radiation therapy for head and neck cancer: Toward an optimal fractionation scheme

et al. 2008

View full text Add to dashboard Cite

show abstract

“…reported a retrospective review of 20 patients with advanced head and neck or pelvic cancers treated similarly. They reported a 94.7% response rate and 90% palliation of symptoms 8 …”

Section: Discussionmentioning

confidence: 98%

Role of concurrent chemoradiotherapy and stereotactic body radiation treatment for palliation of previously untreated head and neck cancers

Thomas

Packianathan

Ahmed

et al. 2020

Precision Radiation Oncology

View full text Add to dashboard Cite

Palliative concurrent chemoradiotherapy has not been well evaluated for patients who are not a candidate for definitive treatment. Even though stereotactic radiotherapy has established a role in the re‐irradiation of recurrent head and neck tumors, its role is not established as a possible primary treatment modality for patients who are not eligible for curative treatment. This article reviews the available literature on the role of chemoradiotherapy and stereotactic radiation for palliation of previously untreated head and neck cancers.

show abstract

Palliation of Pelvic and Head and Neck Cancer with Paclitaxel and a Novel Radiotherapy Regimen

Cited by 29 publications

References 21 publications

Palliative head and neck radiotherapy with the RTOG 8502 regimen for incurable primary or metastatic cancers

Palliative head and neck radiotherapy with the RTOG 8502 regimen for incurable primary or metastatic cancers

Palliative radiation therapy for head and neck cancer: Toward an optimal fractionation scheme

Role of concurrent chemoradiotherapy and stereotactic body radiation treatment for palliation of previously untreated head and neck cancers

Contact Info

Product

Resources

About